trastuzumab deruxtecan,ruxolitinib
novartis,daiichi sankyo,astrazeneca,incyte
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'rux,(-crux),(-trux)', 'destiny,crc,02', 'trastuzumab deruxtecan']
trastuzumab deruxtecan-nxki at a 5.4-mg/kg dose showed numerically higher activity in patients with her2-positive #mcrc, according to findings from the phase 2 destiny-crc02 study. #asco2023 | 
Oncology news and insights from leading researchers and cancer centers.